November 2020 updates to the website

The website has now been updated following November's LSCMMG/JCCCGs

The following drugs have been added/updated:

Dibotermin alfa - For the treatment of acute tibia grade IIIB fractures in adults (as assessed on the Gustilo-Anderson scale), as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation in hospital settings.

Dibotermin alfa - Dibotermin alfa is not recommended in Lancashire and South Cumbria for use outside of the licensed indication for the treatment of non-union long bone fractures.

Melatonin (Circadin®) - For the Treatment of Rapid Eye Movement (REM) Sleep Behaviour Disorder (RBD) in Parkinson’s Disease and Lewy Body Dementia.

Haemophilus type b and Meningococcal group C conjugate vaccine (Menitorix) - Administration in patients with respiratory conditions

Pregabalin - GAD

Rifaximin - Rifaximin as second line antibacterial treatment for the treatment of Small Intestinal Bacterial Overgrowth

VACOcast Diabetic Boot - For the management of foot ulcers in the diabetic population

Oscillating Positive Expiratory Pressure Devices - For Non – Cystic Fibrosis Bronchiectasis

Patiromer for treating hyperkalaemia - For treating hyperkalaemia (TA 623)

Sotagliflozin with insulin - for treating type 1 diabetes (TA 622)

The following guidelines have been added/updated:

Recurrent UTI Prophylactic Antibiotic Pathway

Management of Psoriasis in Primary Care Guideline

Dapagliflozin for the treatment of type 1 diabetes shared care guideline

Apomorphine shared care

Psoriasis: LSCMMG Biologic and High Cost Drug Commissioning Pathway

Over The Counter (OTC) Items That Should Not Be Routinely Prescribed In Primary Care Policy

The following Items will be ratified and added to the website following the next Joint Committee of CCGs (JCCCG) Meeting:

Semaglutide Tablets - For the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise